Overall, these data strongly demonstrate that combination therapy using TGFβ inhibition with Zol can repair existing osteolytic lesions in murine models of myeloma, a novel finding not yet reported in myeloma or other cancer‐induced bone diseases. The gene discussed is TGFB1; the disease is cancer.